Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144
| العنوان: | Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144 |
|---|---|
| المؤلفون: | Ioannis Pozios, Nina A. Hering, Emily Guenzler, Marco Arndt, Sefer Elezkurtaj, Thomas Knösel, Christiane J. Bruns, Georgios A. Margonis, Katharina Beyer, Hendrik Seeliger |
| المصدر: | Journal of Cancer Research and Clinical Oncology. 149:271-280 |
| بيانات النشر: | Springer Science and Business Media LLC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cancer Research, Oncology, General Medicine |
| الوصف: | Purpose Interleukin 6 (IL-6), Oncostatin M (OSM), and downstream effector STAT3 are pro-tumorigenic agents in pancreatic ductal adenocarcinoma (PDAC). Glycoprotein 130 (gp130) is a compound of the IL-6 and OSM receptor complex that triggers STAT3 signaling. SC144 is a small molecule gp130 inhibitor with anticancer activity. This study examines the gp130 expression in human PDAC specimens and the in vitro effects of SC144 in PDAC cell lines. Methods Tissue micro-arrays were constructed from 175 resected human PDAC. The gp130 expression in tumor epithelium and stroma was determined by immunohistochemistry, and survival analysis was performed. Growth inhibition by SC144 was assessed in vitro using BrdU and MTT assays. Western blotting was performed to evaluate the SC144 effect on IL-6 and OSM signaling. Results Gp130 was expressed in the epithelium of 78.8% and the stroma of 9.4% of the tumor samples. The median overall survival for patients with or without epithelial gp130 expression was 16.7 months and 15.9 months, respectively (p = 0.830). Patients with no stromal gp130 expression showed poorer survival than patients with stromal gp130 expression (median 16.2 and 22.9 months, respectively), but this difference did not reach significance (p = 0.144). SC144 inhibited cell proliferation and viability and suppressed IL-6- and OSM-stimulated STAT3Y705 phosphorylation in PDAC cells. Conclusion Gp130 is expressed in the epithelium of most human PDAC, but stromal expression is rare. The small molecule gp130 inhibitor SC144 potently inhibits PDAC progression in vitro and may abrogate IL-6 or OSM/gp130/STAT3 signaling. These results suggest gp130 as a novel drug target for pancreatic cancer therapy. |
| تدمد: | 1432-1335 0171-5216 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d86bcb87dd3be25fdbbdd84f7e3400eaTest https://doi.org/10.1007/s00432-022-04518-9Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d86bcb87dd3be25fdbbdd84f7e3400ea |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14321335 01715216 |
|---|